0001193125-26-053334
SEC filingCogent Biosciences, Inc. reported a net loss of $328.9 million for fiscal year 2025, driven by significant operating expenses of $333.4 million, primarily from research and development costs of $269.8 million and general and administrative expenses of $63.6 million. The company generated $4.4 million in other income, net, including $14.7 million in interest income, partially offset by $3.1 million in interest expense and a $7.2 million loss on debt extinguishment. Comprehensive loss totaled $329.0 million. The balance sheet shows strong liquidity with total assets of $937.6 million, including $910.4 million in current assets ($312.0 million cash and cash equivalents, $588.8 million short-term marketable securities). Total liabilities were $301.2 million, with $222.9 million in convertible senior notes, resulting in stockholders' equity of $636.4 million. Cash flow from operations was negative $264.4 million, while financing activities provided $878.2 million primarily from equity issuances, leading to a net increase in cash of $214.3 million.
Cogent Biosciences, Inc. reported a net loss of $328.9 million for fiscal year 2025, with no revenue reported in the financial statements. The company's operating loss was $333.4 million, driven by total operating expenses of $333.4 million, consisting of $269.8 million in research and development expenses and $63.6 million in general and administrative expenses. Other income, net provided $4.4 million, primarily from $14.7 million in interest income, partially offset by $3.1 million in interest expense and a $7.2 million loss on debt extinguishment. Comprehensive loss totaled $329.0 million, including a $92,000 net unrealized loss on marketable securities. Basic and diluted net loss per share were both $2.00, based on 128.9 million weighted average common shares outstanding.
No revenue was reported in the financial statements for fiscal year 2025. The company appears to be in a pre-revenue stage, with all financial activity focused on research and development operations. The absence of revenue segments or geographic breakdowns in the provided data indicates the company is not yet generating commercial sales from its products or services.
With no revenue reported, traditional margin calculations (gross margin, operating margin) cannot be derived from the available data. The company's cost structure is dominated by research and development expenses, which accounted for 81% of total operating expenses ($269.8 million out of $333.4 million). General and administrative expenses represented the remaining 19% ($63.6 million). The company's net loss margin relative to revenue cannot be calculated due to the absence of revenue figures.
Net cash used in operating activities was $264.4 million for fiscal year 2025, primarily driven by the net loss of $328.9 million, adjusted for non-cash items including $46.1 million in stock-based compensation expense. Investing activities used $399.5 million, mainly for purchases of marketable securities ($687.2 million) partially offset by maturities and sales ($289.2 million). Financing activities provided $878.2 million, primarily from equity issuances including $539.8 million from public offerings and $159.3 million from ATM offerings. The balance sheet shows total assets of $937.6 million, with strong liquidity of $910.4 million in current assets ($312.0 million cash, $588.8 million marketable securities). Total liabilities were $301.2 million, including $222.9 million in convertible senior notes. Stockholders' equity stood at $636.4 million with an accumulated deficit of $1.19 billion.
No forward-looking guidance, strategic priorities, or specific risk factors were provided in the financial data sections of this filing. The company's financial position indicates substantial liquidity with $900.8 million in cash and marketable securities, which should support continued research and development activities. The significant equity financing activities during the year ($878.2 million net cash provided) suggest ongoing capital raising to fund operations. The absence of revenue and continued substantial operating losses indicate the company remains in a development stage with products not yet commercialized.